SPRO — Spero Therapeutics, Inc.

Summary of Spero Therapeutics Q2 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $14.2 million for Q2 2025, up from $10.2 million in Q2 2024, primarily driven by collaboration revenue from GSK.
• R&D Expenses: $10.7 million in Q2 2025, significantly down from $23.7 million in Q2 2024 due to reduced clinical expenses related to the PIVOT-PO study.
• G&A Expenses: Increased to $5.9 million from $5.5 million year-over-year, attributed to higher personnel and professional services costs.
• Net Loss: $1.7 million for Q2 2025, a substantial improvement from a net loss of $17.9 million in Q2 2024. Diluted net loss per share improved to $0.03 from $0.33.

2. Strategic Updates and Business Highlights

• PIVOT-PO Trial Success: The Phase III trial for Tebipenem HBr in complicated urinary tract infections (cUTIs) met its primary endpoint and was stopped early for efficacy, indicating strong potential for the drug.
• Regulatory Plans: GSK plans to submit the trial results for FDA filing by the end of 2025, with potential FDA action anticipated in the second half of 2026.
• Partnerships: Spero retains rights in Japan and certain Asian markets through a partnership with Meiji Seika Pharma, while GSK manages development and commercialization in other territories.
• Financial Milestones: Spero could receive up to $351 million in contingent milestones from GSK, enhancing financial outlook.

3. Forward Guidance and Outlook

• Cash Runway: Current cash and equivalents of $31.2 million, along with $23.8 million in expected milestone payments, are projected to fund operations into 2028.
• Focus on Tebipenem HBr: The company aims to prioritize funding for the regulatory process of Tebipenem HBr, viewing it as the primary value driver.

4. Bad News, Challenges, or Points of Concern

• SPR720 Program Setback: The Phase IIa study for SPR720 did not meet its primary endpoint, raising concerns about its viability. Safety signals, including cases of hepatotoxicity, were noted.
• Market Competition: The company faces challenges in a competitive landscape for cUTIs, particularly with the existing standard of care being IV carbapenem therapy.

5. Notable Q&A Insights

• Capital Allocation Strategy: Management emphasized that the primary focus will be on ensuring Tebipenem HBr progresses through regulatory approval before making further capital allocation decisions, indicating a cautious approach to future investments in business development or pipeline expansion.

Overall, Spero Therapeutics is positioned positively following the successful trial of Tebipenem HBr, though challenges remain with the SPR720 program and competitive pressures in the market. The financial outlook appears stable, supported by strategic partnerships and potential milestone payments.